|
The patients who have used MBVax Coley Fluid are almost
exclusively end-stage, suffering from the many effects of previous treatments
and with few remaining treatment options. Of cancer patients receiving at least
four weeks Coley Fluid therapy, physicians report these results (including
patients continuing to receive therapy):
- 94% of patients have benefited from
therapy including improvement in pain, appetite, depression, mobility, and/or
regression of cancer.
- 70% of patients have achieved
confirmed regression of cancer.
- Twelve patients have achieved
complete remission (no detectable cancer).
Physicians have reported
confirmed regressions in 17 different types of advanced cancer: breast, brain,
cervical, colon, esophageal, liver, lung, lymphoma, melanoma, multiple myeloma,
ovarian, pancreas, prostate, rectal, sarcoma, stomach and tongue. Complete
remissions (no remaining cancer) have been reported in two advanced lymphomas,
eight advanced breast cancers, and one each in advanced lung cancer and stomach
cancer.
|
Number of Patients
|
Type of Cancer |
Complete response no detectable cancer |
Partial response confirmed regression |
Improvement in pain, appetite, depression
and/or mobility |
No improvement |
|
19 |
Breast |
8 |
10 |
1 |
|
|
8 |
Lymphoma |
2 |
5 |
|
1 |
|
6 |
Ovarian |
|
4 |
2 |
|
|
6 |
Prostate |
|
4 |
2 |
|
|
4 |
Liver |
|
1 |
3 |
|
|
4 |
Lung |
1 |
2 |
|
1 |
|
3 |
Colon |
|
2 |
1 |
|
|
3 |
Melanoma |
|
1 |
1 |
1 |
|
2 |
Pancreas |
|
1 |
1 |
|
|
2 |
Sarcoma |
|
1 |
|
1 |
|
2 |
Esophagus |
|
1 |
1 |
|
|
2 |
Brain |
|
1 |
1 |
|
|
1 |
Cervical |
|
1 |
|
|
|
1 |
Gall Bladder |
|
|
1 |
|
|
1 |
Larynx |
|
|
1 |
|
|
1 |
Multiple Myeloma |
|
1 |
|
|
|
1 |
Rectal |
|
1 |
|
|
|
1 |
Stomach |
1 |
|
|
|
|
1 |
Tongue |
|
1 |
|
|
|
68 |
|
12 |
37 |
15 |
4 |
The table is a preliminary summary of all physicians’
reports on patients treated for four or more weeks under the MBVax compassionate
use program. The table may not include every patient treated due to lack of or
inadequate reporting from the administering clinics. MBVax believes these
results are indicative of the results of the entire program. Following are case
summaries of 22 patients from the table.
Case 1 - breast cancer
On diagnosis in 1993, a 6 cm mass was detected in the
left breast. First line therapy was a modified radical mastectomy with
lymph-node dissection; six of 21 lymph nodes were invaded by malignant cells;
patient was staged as IIIA (T3 N1 M0). Chemotherapy with Cytoxan, methotrexate,
and 5FU was given per standard protocol. Patient was started on tamoxifen,
which was discontinued immediately when she developed endometrial cancer for
which she had a total abdominal hysterectomy. In January 2001, she underwent
two additional cycles of chemotherapy. In September 2003, a PET scan
demonstrated multiple lymph nodes and skeletal lesions, and a chest x-ray
revealed a 1.5-cm left mid-lung mass. In January 2004, CT revealed multiple
lung tumors and a bone scan demonstrated progression with new extensive
metastatic disease involving the anterior calvarium, the left sternoclavicular
region, several bilateral ribs, the sternum, the spine throughout its
cervical, thoracic, and lumbar vertebrae, as well as multiple lesions in the
pelvis, and at least two lesions in the right proximal femur. Patient tried
various alternative treatments before starting Coley Fluid in October 2006. A
PET/CT of May 2007 demonstrated “Stable uptake in the left clavicle; stable
right hilar uptake, probably benign; widespread mottled appearance of the
bones, but no sugar uptake, suggesting healed metastatic bone disease."
Patient achieved complete remission.
Case 2 - breast cancer
An 18-year history of breast cancer (invasive ductal
carcinoma) initially treated with radiation and lumpectomy. Two years later,
cancer recurred in the opposite breast and was again operated and radiated,
and subsequent recurrences required a total of 15 lumpectomies. Upon starting
Coley Fluid in December 2006, the patient had an open ulcer on a very enlarged
left breast and half a dozen satellite tumors under the breast, and ultrasound
demonstrated one right-sided nodule and six left-sided nodules with a
non-healing ulcer. Her oncologist advised mastectomy, but she declined. She
had many sub range fevers in the beginning months, and quite a few gaps of
weeks between injections, but graduated to higher fevers as she became more
aggressive in the summer of 2007. Once leukocytosis began, the breast shrank
rapidly over the course of about six weeks. Her breast is entirely normal now,
and there are no residual signs or scars. She was treated with intratumoral
injections only (no intravenous or intramuscular injections). Patient achieved
complete remission.
Case 3 - breast cancer
Patient with metastatic breast cancer received less than
one week Coley Fluid therapy at a foreign clinic. She was very sensitive to
the vaccine and produced fevers above 40C. On return to her home country, she
continued treatment with Coley Fluid. In September 2007, her chest X-ray was
clear and blood work including all tumor markers normal. A bone scan came back
normal. Whole-body PET/CT scan found no metastases. Patient achieved complete
remission.
Case 4 - cervical cancer
Massive, rapidly growing cervical cancer with bone
metastases and large ulcerating tumor on the left leg, patient was not able to
walk. The attending physician stated, "Her cancer was one of the worst I have
ever seen". Following initiation of intravenous Coley Fluid, edema and cancer
pain were reduced and there was a prominent reduction in primary tumor and
bone metastases. After 3 weeks, patient improved to the extent that she was up
and walking, and was sent home from the hospital. On returning home, treatment
was not continued and disease began to progress. Patient subsequently lost to
follow-up.
Case 5 - colon cancer
Large metastatic colorectal cancer with metastases to
pelvic cavity and vagina. After 3 weeks of intravenous Coley Fluid treatment,
there was a dramatic reduction in the tumor (over 70% of volume).
Case 6 - colon cancer
Colon cancer with metastases to bone. Patient had two
previous intra-abdominal surgeries. Approximately 50% reduction of tumor since
starting Coley Fluid intramuscularly.
Case 7 - esophageal cancer
Stage 4 esophageal cancer recurrence after previous
esophagectomy in 2000. In March 2007, patient presented with weight loss,
cough, shortness of breath, difficulty swallowing and weakness. A large
fast-growing pancreatic tumor and smaller lung tumor were diagnosed tumor with
marker CEA measured at 223.8. After intramuscular Coley Fluid, cough was
alleviated, lung function improved and there were no difficulties in
swallowing. In September 2007 patient developed bleeding from the pancreatic
tumor. A PET/CT scan showed partial necrosis of the lung and pancreatic tumors
that may have precipitated the bleeding. Decreased SUV values were seen for
both tumors compared to Mar 07 scan. Bleeding was halted with 15 treatments of
local radiation (not to lung). During period to correct bleeding patient
discontinued vaccine and lung tumor increased in size. Patient reinitiated
Coley Fluid treatment and by March 2008 PET/CT scan showed pancreatic tumor
was dead. The CEA reduced to 2.1 (normal <3) and the patient regained lost
weight and strength. In April, the patient took a 10-day motorcycle trip.
Case 8 - liver cancer
Locally advanced liver cancer. Patient taking
chemotherapy and Coley Fluid intramuscularly. Approximately 70% reduction in
tumor since starting therapy.
Case 9 - lung cancer
Upper left lung carcinoma with metastases kidneys, liver
and bones (female, H 153cm; W 64.3kg [27.5 kg/m2]). After six weeks
intensive (five days weekly) intravenous Coley Fluid therapy, patient had
improved appetite, mood, disappearance of chest pain, and X-ray and CT scans
showed no remaining evidence of cancer. Patient achieved complete remission.
Case 10 - lung cancer
Lung cancer with kidney metastases (H 167cm; W 85kg [30.5
kg/m2]) and a long history arthritis/arthrosis. Tried two courses
of chemotherapy, but felt worse and discontinued. After starting Coley Fluid
patient was able to go up and down stairs more easily, improved sleep. Patient
said, "I can't explain but I feel better, I breathe better, I eat better, I am
better." Chest mass diminished in size. Patient was able to go back to work as
salesman.
Case 11 - lymphoma
Patient with metastatic mediastinal lymphoma diagnosed in
2003 and previously treated with chemotherapy, but due to lack of efficacy and
poor quality of life patient declined further treatment. Began Coley Fluid in
May 2009 with steady improvement in health. Returned to work in November 09.
Patient achieved complete remission.
Case 12 - lymphoma
Patient with Hodgkin lymphoma with enlargement of nodes
in the neck. No previous treatments. The patient had one 3 cm node and a
cluster of small lymph nodes that could be felt by palpation. The largest node
was reduced to 1.5 cm and was more mobile and the small cluster of nodes was
less palpable. There have been no intratumoral or peritumoral injections.
Patient discontinued vaccine in Nov 07 and by Mar 08 tumors had grown back to
their original size. Patient then resumed intravenous Coley Fluid and tumors
again started to decrease. Patient then discontinued treatment and tumors
regrew. In the summer of 2009, the patient began intravenous Coley Fluid
treatment again achieving a 50% reduction in his tumors with moderate fevers.
Case 13 - lymphoma
Patient with mantle cell lymphoma. Tumors on the neck
were reduced to one-quarter original size after three weeks of intramuscular
Coley Fluid treatment. Patient subsequently received a stem cell transplant
with chemotherapy and is presently in remission.
Case 14 - lymphoma
Patient with follicular lymphoma originally diagnosed in
1995 as stage 4 due to bone marrow involvement. Many previous chemotherapy
treatments. In 2007 prior to Coley Fluid therapy there were several large
nodes in groin, a small node on clavicle, and many enlarged nodes in abdomen
causing swelling and itchiness, also pain below liver, and hand and foot
cramps. Due to hydronephrosis in left kidney, a stent was inserted into the
left ureter. Coley Fluid therapy was injected intratumorally into groin.
Improved kidney function led to permanent removal of ureter stent in Dec 08.
External nodes in groin regressed, liver pain disappeared, swelling of abdomen
reduced, platelets and liver function tests improved, itching and cramps have
disappeared. CT scans up to Nov 09 show continuing shrinkage of tumors with
the disappearance of many lesions, including nodes in groin. Now active,
hiking and continuing Coley Fluid.
Case 15 - lymphoma
Patient with B cell lymphoma with one mediastinal tumor
(3.6 cm) and one neck tumor measuring 5.9 cm. The latter tumor was compressing
his trachea and his carotid artery by 75%. Following alternating intramuscular
and intravenous Coley Fluid, a CT scan showed a 51% reduction in the neck
tumor and a stable mediastinal mass. Following a second course of Coley Fluid,
the patient's bloodworm normalized and a subsequent PET/CT scan showed only a
ring of hypermetabolic activity with a necrotic core in both tumors. All
previous tissue injection sites were hypermetabolic on the PET/CT as were
draining lymph nodes (this would represent non-malignant inflammation). The
carotid artery now shows normalized blood flow and the cough has disappeared.
Case 16 - lymphoma
Patient with large inoperable left sided mantle cell
lymphoma. The tumor under his left arm extended to the sternum with associated
enlarged nodes. Patient could not lower his arm due to the extensive size of
the tumor. The patient was treated with Coley Fluid intratumorally only,
beginning in April 2009. After 5 months of treatment, the tumor regressed to
size of a lemon and patient could lower his arm with greater mobility.
Malignant nodes opened up twice during treatment with drainage of necrotic
tumor tissue. The Coley Fluid caused prolonged fevers lasting up to 2 days,
which were often associated with nausea and vomiting. Despite regression of
the primary tumor, the inguinal nodes in the groin began to enlarge. Due to
side effects, patient decided to discontinue treatment in October 2009 and
appeared in poor health. In April 2010, the patient returned to his physician
who observed that the tumor under his arm had disappeared and the nodes in the
groin regressed. The patient has now gone back to his favorite pastime,
golfing.
Case 17 - multiple myeloma
Patient had two previous bone marrow transplants with
chemotherapy. She had a history of increasing tumor markers (M protein) before
starting the therapy. Patient began Coley Fluid in October 2006. In January
2007, a skeletal survey, bone marrow biopsy, and 24 hour urine test were
negative for myeloma. Subsequently discontinued vaccine in Nov 07. Follow-up
MRI in Apr 09 was negative. Tumor markers stable showing a low residual M
protein level up to last follow-up in Feb 2010. Patient is physically well.
Case 18 - ovarian cancer
Patient had multiple cancerous lesions in her abdomen
before treatment. A CT scan in Dec 2006 showed disappearance of all lesions,
except one. Her hemoglobin improved, as did her strength and energy. Adverse
effects included an increase in bone pain following the vaccination. This is
believed to be due to stimulation of the bone marrow to produce more immune
cells as the patient did not have evidence of cancer in the bone. This patient
also developed a superficial staphylococcal infection near points of
injection. This was successfully treated with antibiotics. Finally, this
patient was overweight and lost about 15 pounds since the start of the
therapy.
Case 19 - ovarian cancer
Ovarian cancer in abdominal region. Intramuscular Coley
Fluid treatment led to reduced ascites, tumor shrinkage by approximately 50%,
improved appetite and decreased tumor pain.
Case 20 - ovarian cancer
Patient with metastatic ovarian cancer received two weeks
intravenous Coley Fluid therapy at an international clinic. CA 125 marker in
the thousands declined to 36 following two weeks of intravenous Coley Fluid
therapy. Patient was unable to continue therapy on return home.
Case 21 - pancreatic cancer
Patient was rapidly losing weight (2 pounds per day) when
diagnosed in December 2007 with stage 4 pancreatic cancer. Pre-treatment, a CT
scan showed the largest tumor, surrounding the mesenteric vein and artery, to
be 15.5 cm. There were metastases in the liver and possibly bone. Patient
received three weeks Coley Fluid therapy at an international clinic. After
three weeks therapy, ultrasound examination showed the large pancreatic tumor
had reduced to 9.4 cm and four liver metastases previously seen on CT were no
longer visible. The patient regained some weight, and digestion and liver
function tests improved. Patient returned to home country where therapy could
not be continued. Disease progressed.
Male, 60 years, with locally advanced ulcerated stage IV
stomach cancer. Tumor was greater than 5 cm with metastases to surrounding
lymph nodes. Patient received 55 intramuscular Coley Fluid treatments. Patient
achieved complete remission.
|